Welcome : Guest

ARTIFICIAL ORGANS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Artificial Organs in US$ Million by the following Product Segments: Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas, and Artificial Lungs. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 48 companies including many key and niche players such as -

Abbott Diabetes Care, Inc.
Abiomed, Inc.
Asahi Kasei Medical Co., Ltd.
Baxter International, Inc.
F.Hoffmann-La Roche Ltd.

Click here to request a full list of companies covered in the report...

Code: MCP-1126
Price: $4500
Companies: 48
Pages: 248
Date: August 2016
Market Data Tables: 65
 



TABLE OF CONTENTS


  ARTIFICIAL ORGANS (Complete Report) Pages : 248   | $4500

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Artificial Organs Revolutionize Medical Technology Industry.....II-1
Growth Drivers.....II-1
1$100
   Growth Inhibitors.....II-21$100
   Artificial Organs Poised to Witness Significant Demand.....II-3
The United States – A Dominant Force in the Artificial Organs Market.....II-3
1$100
   Artificial Kidneys Garner a Larger Pie in the Artificial Organs Market.....II-41$100
   Competitive Scenario.....II-5
Technological Advancements Spearheading Growth.....II-5
1$100
   Artificial Heart.....II-6
Table 1: Artificial Heart Transplants Worldwide (1969-2016): Percentage Share Breakdown of Number of Heart Transplants (includes corresponding Graph/Chart).....II-6
1$350
   Medical Community Poised to Embrace Artificial Heart.....II-71$100
   Ventricular Assist Devices.....II-81$100
   Select Ventricular Assist Devices.....II-9
Artificial Mechanical Heart Valves Come of Age.....II-9
1$100
   Artificial Kidney.....II-10
Kidney Failure: A Major Concern.....II-10
Artificial Kidney or Dialyzers Market.....II-10
1$100
   Major Initiatives in the Artificial Kidney Space.....II-11
The Kidney Project.....II-11
1$100
   Current Status of the Kidney Project.....II-121$100
   Wearable Artificial Kidney Holds Promise to Transform Dialysis.....II-13
Artificial Liver.....II-13
Liver Support System to Provide Precious Time for Liver Transplantation.....II-13
1$100
   Liver Assist Devices Competitive Landscape.....II-14
Select Liver Assist Devices.....II-14
Artificial Pancreas.....II-14
Artificial Pancreas Device System Market Presents Lucrative Opportunities.....II-14
1$100
   Market Overview.....II-151$100
   Scientific Community Inches towards Artificial Pancreas System.....II-161$100
   Competition and Key Developments in Artificial Pancreas Space.....II-171$100
   Artificial Pancreas Status in the US.....II-181$100
   Key Concerns.....II-191$100
   The Grim Reality of Mounting Economic and Social Burden of Cardiovascular
  Disease.....II-20
Table 2: Prevalence of Heart Failure in Select Countries (includes corresponding Graph/Chart).....II-20
1$350
   Artificial Pancreas System (APS) – The Future of Diabetes Care.....II-21
Higher Development Costs and Lengthy Regulatory Process – Stumbling Blocks for Product
  Commercialization.....II-21
1$100
   Lack of Requisite Expertise – Hindering Implantation Process.....II-22
Xenotransplantation – Other Alternative to Donor Organ Shortage.....II-22
Artificial Organs from Cloned Animal Cells – A Promising Trend.....II-22
Immunosuppressants Hold Promise in Artificial Organs Market.....II-22
Move towards Smaller Implantable Devices.....II-22
1$100
   Barriers to Entry Significantly High in Dialyzers Market.....II-23
Reuse of Dialyzers – A Major Issue in Dialysis Industry.....II-23
Poor Reimbursement Environment Stymies Innovation.....II-23
Product Recalls – A Major Blow to the Manufacturers.....II-23
1$100
   Higher Cost of Artificial Organs Hampers Broader Adoption.....II-241$100
   Major Issues Related to Artificial Organs.....II-25
Financial.....II-25
1$100
   Legal.....II-26
Ethical.....II-26
Social.....II-26
1$100
   Aging Population: A Strong Growth Driver.....II-27
Global Aging Population Statistics – Opportunity Indicators.....II-27
Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart).....II-27
1$350
   Table 4: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart).....II-281$350
   Table 5: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart).....II-291$350
   Table 6: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart).....II-301$350
   Expanding Pool of ESRD and CKD Patients – The Major Growth Driver for Kidney Dialysis
  Treatment.....II-31
Table 7: Increasing Number of ESRD Patients Worldwide: 2014-2018 (includes corresponding Graph/Chart).....II-31
1$350
   Table 8: ESRD Prevalence in Select Countries (2014): Number of ESRD Patients Per Million Population in EU-28, Japan, Taiwan, USA and Global (includes corresponding Graph/Chart).....II-32
Dialysis Market to Stage Steady Growth Amid Rising Prevalence of Kidney
  Diseases.....II-32
1$350
   Table 9: Global Population of ESRD Patients Undergoing Treatment by Type of Modality (2010, 2015E & 2020P): Percentage Breakdown of Patients Undergoing Dialysis Therapy, and Kidney Transplantation (includes corresponding Graph/Chart).....II-331$350
   Developed Markets Maintain Lead, Emerging Markets to Dictate Momentum.....II-34 1$100
   Table 10: Worldwide Distribution of Dialysis Patients by Geographic Region (2015): Percentage Breakdown of Patient Population (includes corresponding Graph/Chart).....II-35
Rising Incidence of Diabetes: Opportunity Indicator for Artificial Pancreas.....II-35
Growing Number of Type 1 Diabetes Cases.....II-35
1$350
   Global Diabetic Statistics - Opportunity Indicators.....II-36
Table 11: Top 10 Countries for Number of Children with Type 1 Diabetes (2015) (includes corresponding Graph/Chart).....II-36
1$350
   Table 12: Global Prevalence of Type 1 Diabetes in Children by Region (2015) (includes corresponding Graph/Chart).....II-37
A “Silent Killer” in Both Developed as well as Developing Nations.....II-37
1$350
   Table 13: Global Diabetes Mellitus Incidence among Ages 20-79 (2015 & 2040P): Prevalence (in Million) and Percentage Share by Geographic Region (includes corresponding Graph/Chart).....II-381$350
   Table 14: Top Ten Countries Worldwide with the Highest Number of People (in the Age Group 20-79 Years) with DM (in Millions): 2015 (includes corresponding Graph/Chart).....II-39
Dialysis Patient Population: An Opportunity Indicator for Artificial KIdneys.....II-39
1$350
   Table 15: Global Dialysis Patient Population by Geographic Region/Country (2014-2018): Breakdown of Patient Population for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart).....II-40
Distribution of Dialysis Patients by Modality.....II-40
1$350
   Table 16: Worldwide Dialysis Patient Population by Treatment Modality (2015): Percentage Breakdown of Hemodialysis (HD) Patients and Peritoneal Dialysis (PD) Patients for US, Japan, European Union, and Rest of World (includes corresponding Graph/Chart).....II-411$350
   Table 17: Global Dialysis Patient Population Distribution by Modality for Select Countries (2015): Percentage Breakdown of Hemodialysis (HD) Patients and Peritoneal Dialysis (PD) Patients for US, China, Japan, Brazil, Mexico, Germany, India, Taiwan, Turkey, Thailand, Korea, Italy, France, Egypt, and Malaysia (includes corresponding Graph/Chart).....II-421$350
   3d Bioprinting – A Game Changer for the Artificial Organs Industry.....Ii-431$100
   Application of 3D-Printing in the Medical Field.....II-441$100
   3D Printing Revolutionizing the Medical Industry’s Artificial Organ Development
  Segment.....II-45
1$100
   Issues to be Tackled.....II-461$100
   Sophisticated Software – A Key Element for 3D Printing.....II-471$100
   Bioprinters to Aid Medical Students.....II-48
Bioprinters to Print Organs.....II-48
Bioprinters for Printing Defective Organs for Surgeons to Practice On.....II-48
2$200
   New Artificial Pancreas with Sensor to Improve Insulin Management.....II-50
Researchers at the University of California Come Up with an Artificial Kidney.....II-50
1$100
   Wearable Artificial Kidney Enters the US FDA’s EAP Pipeline.....II-511$100
   New Artificial Pancreas System to Improve Diabetes Management.....II-52
Production of 3D-like Artificial Organs in a Device that Works like a Cotton Candy
  Machine.....II-52
1$100
   Harvard Scientists Create Tissue Containing Blood Vessels.....II-53
University of Washington Researchers Create Communicating Yeast Cells.....II-53
1$100
   ALung Technologies Develops Hemolung RAS Artificial Lung.....II-541$100
   The First Transplant of Small Sized Artificial Heart for Petite People Carried Out in
  California.....II-55
Scientists Define Morphospace to Evaluate Viability of Artificial Organs.....II-55
2$200
   Artificial Organs.....II-57
Categorization of Artificial Organs.....II-57
External Artificial Organs.....II-57
Internal or Implantable Artificial Devices.....II-57
Artificial Heart.....II-57
1$100
   Total Artificial Heart (TAH).....II-58
Ventricle Assist Device (VAD).....II-58
Table 18: Distribution of Various Uses of VADs (includes corresponding Graph/Chart).....II-58
Right Ventricular Assist Systems (RVAS).....II-58
Left Ventricular Assist Systems (LVAS).....II-58
Categorization of LVAS.....II-58
1$350
   First Generation LVAS.....II-59
Second Generation LVAS.....II-59
Third Generation LVAS.....II-59
1$100
   Benefits of LVAS.....II-60
Major Limitations and Complications of VADs.....II-60
1$100
   Infection.....II-61
Internal Bleeding.....II-61
Thrombus.....II-61
Dependability.....II-61
1$100
   Cost.....II-62
Natural Human Heart.....II-62
Heart Diseases.....II-62
Congenital Heart Disease.....II-62
Congestive Heart Failure.....II-62
Types of Heart Failure.....II-62
1$100
   Diastolic Heart Failure.....II-63
Systolic Heart Failure.....II-63
Artificial Heart - A Historical Perspective.....II-63
1$100
   Major Milestones in Artificial Heart Development.....II-64
Jarvik-7.....II-64
AbioCor Total Artificial Heart.....II-64
1$100
   CardioWest Temporary Total Artificial Heart.....II-65
DuraHeart LVAS.....II-65
1$100
   HeartSaverVAD.....II-66
VentrAssist Left Ventricular Assist Device.....II-66
1$100
   Artificial Kidney (Dialyzer).....II-67
Limitations of Artificial Kidney.....II-67
Types of Dialysis.....II-67
Hemodialysis.....II-67
1$100
   Peritoneal Dialysis.....II-681$100
   Advancements in Artificial Kidney Technology.....II-69
Bioartificial Kidneys.....II-69
Limitations of Bioartificial Kidneys.....II-69
1$100
   Hindrances to Develop Implantable Artificial Kidney.....II-70
Artificial Kidneys - A Historical Perspective.....II-70
Artificial Liver.....II-70
1$100
   Overdose of Drugs – A Leading Cause for Liver Damage.....II-711$100
   Categorization of Liver Devices.....II-72
Mechanical Systems.....II-72
Liver Dialysis Unit™.....II-72
Bio-Artificial Systems.....II-72
1$100
   Capillary Hollow Fiber Systems.....II-73
Direct Perfusion Systems.....II-73
Entrapment Based Systems.....II-73
1$100
   Major BAL Devices.....II-74
Extracorporeal Liver Assist Device (ELAD).....II-74
Hybrid Artificial Liver Support System.....II-74
1$100
   History of Artificial Liver.....II-75
Liver Assist Devices – Major Milestones.....II-75
Nonbiological Method Introduction Time Line.....II-75
1$100
   Biological Method Introduction Time Line.....II-76
Artificial Pancreas.....II-76
1$100
   Insulin Pumps - Historical Perspective.....II-77
Bioartificial Pancreas.....II-77
1$100
   Nanotechnology in Artificial Pancreas.....II-78
Artificial Lungs (Oxygenator).....II-78
About Human Lungs.....II-78
1$100
   Types of Artificial Lung.....II-79
Intravenous Membrane Oxygenator.....II-79
Hattler Respiratory Catheter.....II-79
1$100
   MC3 Pulmonary Assist Device.....II-80
In-Series.....II-80
In-Parallel.....II-80
BioLung.....II-80
Heart-Lung Bypass Machine.....II-80
Role of Artificial Lungs during Surgery.....II-80
1$100
   Direct Contact Device.....II-81
Indirect-Contact Type-Membrane Devices.....II-81
Biorubber to be used in Artificial Lungs.....II-81
History of Artificial Lungs.....II-81
An Overview of Tissue Engineering.....II-81
2$200
   Introduction to Biomaterials.....II-831$100
   Europe and the United States Lead the Global Organ Transplants Market.....II-84
Table 19: Global Organ Transplants Market (2014 & 2015): Number of Actual Deceased Organ Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-84
1$350
   Table 20: Global Organ Transplants Market (2014 & 2015): Number of Living Organ Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-85

Table 21: Global Organ Transplants Market (2014): Number of Actual Donors After Cardiac Death Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-85
1$350
   Table 22: Global Heart Transplants Market (2014): Number of Transplants Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-86

Table 23: Global Kidney Transplants Market (2014): Number of Deceased Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-86
1$350
   Table 24: Global Kidney Transplants Market (2014): Number of Living Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-87

Table 25: Global Liver Transplants Market (2014): Number of Deceased Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-87
1$350
   Table 26: Global Liver Transplants Market (2014): Number of Living Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-88

Table 27: Global Pancreas Transplants Market (2014): Number of Transplants Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-88
1$350
   Table 28: Global Lung Transplants Market (2014): Number of Transplants Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-89
Sources of Donor Organs.....II-89
1$350
   Table 29: US Kidney Donations by Donor Type - Cadaveric and Living for Years 2010 through 2016 (includes corresponding Graph/Chart).....II-90

Table 30: US Liver Donations by Donor Type - Cadaveric and Living for Years 2010 through 2016 (includes corresponding Graph/Chart).....II-90
1$350
   Table 31: US Heart Donations by Cadaveric Donor Type for Years 2010 through 2016 (includes corresponding Graph/Chart).....II-91

Table 32: US Lung Donations by Donor Type - Cadaveric and Living for Years 2010 through 2016 (includes corresponding Graph/Chart).....II-91
1$350
   Table 33: US Pancreas Donations by Donor Type - Cadaveric and Living for Years 2010 through 2016 (includes corresponding Graph/Chart).....II-92

Table 34: European Organ Transplants Market (2014 & 2015): Number of Actual Deceased Organ Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-92
1$350
   Table 35: European Organ Transplants Market (2014 & 2015): Number of Living Organ Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart).....II-93
Shortage of Donor Organs Restricts Transplantation Procedures.....II-93
1$350
   Table 36: Waiting List of Patient Registrations in the US by Organ Type: As of July 2016 (includes corresponding Graph/Chart).....II-94
Organ Rejection – A Major Barrier to Transplantation.....II-94
Other Issues for Organ Transplantation.....II-94
Illegal Organ Trafficking – A Risky Proposition.....II-94
1$350
   Ethical Concerns in Transplants.....II-95
Bioethical Issues Hinder Organ Donation Process.....II-95
Increasing Consent Rates – A Key Factor.....II-95
Combined Organ Transplantation – Gaining Attention.....II-95
1$100
   Transplant Tourism – Creating Brighter Avenues.....II-961$100
   Regulatory Environment in the US.....II-971$100
   Regulatory Environment in Europe.....II-981$100
   Medtronic Launches MiniMed(TM) 640G System.....II-99
Pandorum Develops Artificial Human Liver Tissue.....II-99
1$100
   Medtronic and HeartWare International Ink Merger Agreement.....II-100
SynCardia Systems Inks an Agreement with Versa Capital Management.....II-100
Vivonics Sells Artificial Lung Technology to Lung Biotechnology PBC.....II-100
Insulet Corporation Enters into a Partnership and License Agreement with Mode
  AGC.....II-100
Cellnovo Group Enters into a Partnership with TypeZero.....II-100
St. Jude Medical Acquires Thoratec.....II-100
1$100
   Debiotech Collaborates with ARTORG Center to Develop Artificial Pancreas.....II-101
DreaMed Diabetes Enters into an Agreement with Medtronic.....II-101
Breethe Acquires Exclusive Rights from University of Maryland.....II-101
SynCardia Systems Bags FDA Approval for SynCardia Temporary Total Artificial Heart’s
  Destination Therapy Study.....II-101
HeartWare International Bags Approval from Health Canada for HeartWare® Ventricular
  Assist System.....II-101
Alung Technologies Announces Participation in the Pivotal Trial of ECCO2R
  Technology.....II-101
ALung Technologies Announces EAP Designation for Hemolung RAS.....II-101
1$100
   Debiotech, AWAK and Neokidney Development Ink Join Venture Agreement.....II-102
Carmat Implants Artificial Heart.....II-102
Baxter International Acquires Gambro.....II-102
Thoratec Acquires DuraHeart® II from Terumo.....II-102
Sunshine Heart Enters into Collaboration with Minnetronix(R).....II-102
TandemDiabetes Care Enters into a Partnership with JDRF.....II-102
1$100
   Abbott Diabetes Care, Inc. (USA).....II-103
Abiomed, Inc. (USA).....II-103
Asahi Kasei Medical Co., Ltd. (Japan).....II-103
1$100
   Baxter International, Inc. (USA).....II-104
F.Hoffmann-La Roche Ltd. (Switzerland).....II-104
1$100
   Fresenius Medical Care AG & Co. KGaA (Germany).....II-105
HeartWare International, Inc. (USA).....II-105
Jarvik Heart, Inc. (USA).....II-105
1$100
   Medtronic, Inc. (USA).....II-106
Nikkiso Co., Ltd. (Japan).....II-106
Nipro Corporation (Japan).....II-106
1$100
   SynCardia Systems, Inc. (USA).....II-107
Terumo Heart, Inc. (USA).....II-107
Thoratec Corp. (USA).....II-107
1$100
   Toray Medical Co., Ltd. (Japan).....II-108
Vital Therapies, Inc. (USA).....II-108
Xenios AG (Germany).....II-108
1$100
   Table 37: World Recent Past, Current & Future Analysis for Artificial Organs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1091$350
   Table 38: World Historic Review for Artificial Organs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1101$350
   Table 39: World 14-Year Perspective for Artificial Organs by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-1111$350
   Table 40: World Recent Past, Current & Future Analysis for Artificial Organs by Product Segment - Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1121$350
   Table 41: World Historic Review for Artificial Organs by Product Segment - Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1131$350
   Table 42: World 14-Year Perspective for Artificial Organs by Product Segment - Percentage Breakdown of Dollar Sales for Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-1141$350
   Table 43: World Recent Past, Current & Future Analysis for Artificial Kidneys/Dialyzers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa, and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1151$350
   Table 44: World Historic Review for Artificial Kidneys/Dialyzers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa, and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1161$350
   Table 45: World 14-Year Perspective for Artificial Kidneys/Dialyzers by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa, and Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-1171$350
   Table 46: World Recent Past, Current & Future Analysis for Insulin Pumps (External) by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1181$350
   Table 47: World Historic Review for Insulin Pumps (External) by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1191$350
   Table 48: World 14-Year Perspective for Insulin Pumps (External) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-1201$350
   A. Market Analysis.....III-1
SynCardia’s temporary Total Artificial Heart: The Only FDA Approved Artificial
  Heart.....III-1
1$75
   Ageing Demographics: A Major Driving Factor for Artificial Organs Market.....III-2
Table 49: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-2
1$200
   Surging Diabetic Population Spurs Demand.....III-3
Table 50: Prevalence of Diabetes Mellitus in North America (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for the US, Canada and Mexico (includes corresponding Graph/Chart).....III-3
1$200
   Table 51: The US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart).....III-41$200
   Table 52: The US Diabetes Prevalence (in 000’s) for 2010-2017P (includes corresponding Graph/Chart).....III-5

Table 53: Diabetes Prevalence in the US by Type: 2013 (includes corresponding Graph/Chart).....III-5
1$200
   Table 54: Diabetes Prevalence by Ethnicity (includes corresponding Graph/Chart).....III-6
Artificial Pancreas System (APS): The Future of Diabetes Management.....III-6
2$400
   Artificial Pancreas Status in the US.....III-8
Wearable Artificial Kidney Holds Promise to Transform Dialysis.....III-8
1$75
   Product Introduction.....III-9
Strategic Corporate Developments.....III-9
2$150
   Focus on Select Key Players.....III-115$375
   B. Market Analytics.....III-16
Table 55: The US Recent Past, Current & Future Analysis for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-16
1$200
   Table 56: The US Historic Review for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-171$200
   A. Market Analysis.....III-18
Market Analysis.....III-18
1$75
   Table 57: Dialysis Patient Population by Geographic Region/Country (2014-2018): Breakdown of Patient Population for Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart).....III-191$200
   Table 58: Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region.....III-201$200
   Table 59: Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka.....III-21

Table 60: Prevalence of Diabetes Mellitus in Western Asia, Pacific Regions (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region.....III-21
1$200
   Table 61: Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region.....III-221$200
   Table 62: Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region.....III-231$200
   Table 63: Prevalence of Diabetes Mellitus in Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region.....III-24
New Artificial Pancreas System to Improve Diabetes Management.....III-24
1$200
   EU-Supported Artificial Pancreas Project to Provide Competitive Edge to
  Europe.....III-25
1$75
   Product Introduction.....III-26
Strategic Corporate Developments.....III-26
1$75
   Focus on Select Players.....III-273$225
   B. Market Analytics.....III-30
Table 64: Rest of World Recent Past, Current & Future Analysis for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-30
1$200
   Table 65: Rest of World Historic Review for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-311$200
  
Total Companies Profiled: 48 (including Divisions/Subsidiaries - 56)

Region/Country Players

The United States 25 Japan 10 Europe 15 France 3 Germany 5 The United Kingdom 2 Rest of Europe 5 Asia-Pacific (Excluding Japan) 4 Middle East 2
Click here to request a full table of contents and more details on this project.